{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-AZA%29+group+3&page=2", "query": { "intervention": "5-Azacytidine (5-AZA) group 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-AZA%29+group+3&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-AZA%29+group+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:52:57.253Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06158100", "title": "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Antonio M Jimenez Jimenez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2024-12-04", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06158100" }, { "nct_id": "NCT00260832", "title": "Trial of Decitabine in Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine or Supportive Care", "type": "DRUG" }, { "name": "Dacogen (decitabine) only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 485, "start_date": "2005-11", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 37, "location_summary": "Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260832" }, { "nct_id": "NCT03572387", "title": "A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "5-Azacitidine", "type": "DRUG" }, { "name": "all trans retinoic acid", "type": "DRUG" }, { "name": "Lupron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 14, "start_date": "2018-08-20", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03572387" }, { "nct_id": "NCT01200004", "title": "Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Grifola Frondosa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 1, "start_date": "2012-04", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200004" }, { "nct_id": "NCT01333046", "title": "Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "Antigen-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "Dose-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "azacytidine and multiTAA T cells Stage", "type": "BIOLOGICAL" }, { "name": "Pediatric multiTAA T cells Stage", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2012-01", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01333046" }, { "nct_id": "NCT00906334", "title": "Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "ON 01910.Na", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2009-05", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906334" }, { "nct_id": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "FHD-286", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-02-03", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283094" }, { "nct_id": "NCT04588922", "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "SLS009", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 160, "start_date": "2021-05-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588922" }, { "nct_id": "NCT00569010", "title": "Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-12", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569010" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-09T18:52:57.253Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" } ] }